GPR183

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

GPR183是一种趋化受体，以其在B细胞成熟中的作用而闻名，内源性配体是氧甾醇7α,25-二羟基胆固醇(7α,25-OHC)。 GPR183可用于炎症性肠病（IBD）的研究。

GPR183 is a chemotactic receptor known for its role in the maturation of B cells, and the endogenous ligand is the oxysterol 7α,25-dihydroxycholesterol (7α,25-OHC). GPR183 can be used in research on inflammatory bowel disease (IBD).

SAE-14 (compound SAE-14) can able to antagonize 7α, 25-OHC–induced calcium mobilization with an IC50 value below 50 nM. Cell Viability Assay Cell Line:The human leukemia (HL)-60 cells Concentration:5×of the antagonist Incubation Time:15 min Result:Had GPR183-specific (IC50: 28.5nM) and abolished 7a, 25-OHC–induced calcium mobilization in the HL-60 cells.

SAE-14 (compound SAE-14) (i.th.; 2.9 μM; once) can reverse nerve injury-induced allodynia in mice. Animal Model:Male and female ICR mice Dosage:2.9 μM Administration:intrathecal (i.th.) injections; 2.9 μM; once Result:Reversed CCI-induced mechanical allodynia in a time-dependent manner.

3-(3,4-difluorophenyl)-N-[3-fluoro-5-(morpholin-4-yl)phenyl]propanamide

Others

Other Targets

——

——

——

1241280-25-0

364.368

C19H19F3N2O2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (274.45 mM)

Fc1cc(NC(=O)CCc2ccc(F)c(F)c2)cc(c1)N1CCOCC1

——

(-20℃)

With Ice Pack

≥ 2 years